Analysis Of The Impact Of Centralized Drug Procurement On The Innovation Efficiency Of Pharmaceutical Enterprises

In order to solve the widespread problem of "expensive medical care",the country has successively implemented a series of medical reform measures.In 2018,China’s deepening of medical reform entered a new stage,and will gradually form a mainstream drug procurement model of "volume procurement,volume and price linkage,and integration of bidding and procurement" by 2025.However,centralized procurement has a significant impact on the financial indicators of pharmaceutical enterprises,and therefore on the R&D and innovation efficiency on which pharmaceutical enterprises rely for survival.The research objective of this topic is to take Fosun Pharmaceutical as an example,measure the R&D innovation efficiency of listed pharmaceutical companies participating in centralized procurement in China,analyze the impact of the implementation of centralized procurement policy on participating pharmaceutical companies and explore its impact path.Therefore,this study specifically includes the following two aspects:(1)Using the Malmquist index model of DEA,taking Fosun Pharmaceutical as the representative of the bid-winning pharmaceutical enterprises,measure the dynamic R&D innovation efficiency before and after the bid winning,and evaluate the change of the R&D innovation efficiency level of China’s participating pharmaceutical enterprises;(2)Select the pharmaceutical enterprises participating in the centralized procurement bidding in China,measure their innovation efficiency,and use the panel multi-period DID model to test,and conduct in-depth analysis of the path of the impact of centralized procurement on innovation efficiency.This study found that active participation in centralized procurement will have a significant positive effect on the innovation efficiency of listed pharmaceutical enterprises.The specific performance is that the impact coefficient is 0.2585,which is positive,that is,participation in centralized procurement will effectively improve the innovation efficiency of listed pharmaceutical enterprises.Finally,based on the conclusions drawn from empirical research,this article provides certain suggestions and opinions for government departments and different types of enterprises to assist in the better implementation of drug centralized procurement policies.